News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Market source Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
JP Morgan has maintained an "Overweight" rating for Viking Therapeutics (VKTX) but lowered its price target from $75 to $65, reflecting cautious optimism amid challenges in the biotechnology sector. The company has a GF Score™ of 34/100, indicating below-average performance in key financial metrics, …
Viking Therapeutics (VKTX) recently expanded its financing options by filing a $500 million at-the-market follow-on offering and an omnibus shelf registration, following a Q2 2026 net loss of US$128.02 million and previous fundraising of US$159.59 million. This move aims to provide balance sheet flexibility …
J.P. Morgan has reiterated its Buy rating for Viking Therapeutics (VKTX.US) but has revised its target price downwards to $65. This adjustment reflects an updated outlook on the company's valuation while still recommending the stock to investors.
Viking Therapeutics (VKTX) recently reported wider Q2 losses and increased its funding flexibility through new equity offerings. Despite a recent 21% share price drop, the company has strong long-term returns. Analysts question if its current valuation, which pegs fair value at $92.72 (64.1% undervalued), …
Shares in Viking Therapeutics (NASDAQ: VKTX) declined by 18.6% in July, according to data from S&P Global Market Intelligence. The decline came during a slow month for newsflow in its pipeline, as investors began to fret about the company's financial position. Viking Therapeutics' quiet …
Viking Therapeutics (NASDAQ:VKTX) has received a "Moderate Buy" consensus recommendation from brokerages, with an average 12-month price target of $97.88, significantly higher than its current share price. Despite recent insider stock sales by the CFO and CEO to cover tax obligations, institutional investors maintain …
Viking Therapeutics recently reported a wider Q2 net loss and expanded its funding options through a universal shelf registration and a $500 million at-the-market stock offering. While these moves provide capital to advance its obesity drug candidate VK2735 through trials, they also highlight the …
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Why Viking Therapeutics' VK2735 News Matters For Investors Viking Therapeutics (VKTX) has drawn fresh …
In late July 2026, Viking Therapeutics reported Q2 and first-half net losses of US$128.02 million and US$286.35 million respectively, while also filing a US$500 million at-the-market equity offering and an omnibus shelf registration covering multiple securities types. Despite these wider losses and fresh financing …
Viking Therapeutics (VKTX) could unlock substantial additional opportunities for VK2735 through less PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign …
Viking Therapeutics is considered a highly speculative investment due to its clinical-stage status, limited operating history, and expected substantial operating losses. The company's reliance on licensed technologies from Ligand Pharmaceuticals and the uncertain prospects of its drug candidates further elevate its risk profile for …
Viking Therapeutics President Brian Lian recently sold US$4.9 million worth of stock, representing 6.3% of his holding. While insiders sold more than they bought over the last year, the company still reports 2.4% insider ownership, which suggests reasonable alignment with shareholders. The article notes …
Viking Therapeutics reported a net loss of $286.3 million for the first half of 2026, widening from $111.2 million a year prior, due to increased R&D spending on its obesity and NASH drug pipeline. Despite the losses, the company maintains strong liquidity with $501.7 …
Viking Therapeutics (VKTX) reported a narrower-than-expected loss of $1.10 per share for Q2 2026, surpassing analyst estimates of $1.23, although its net loss widened compared to the previous year due to increased R&D spending. The company is advancing its lead obesity drug candidate, VK2735, …
Viking Therapeutics (NASDAQ: VKTX) stock decreased by 4.49% despite reporting a narrower-than-expected net loss of $1.10 per share for the quarter ending June 30. This loss was primarily due to increased R&D costs which nearly doubled. The company maintains a strong cash position and …
Viking Therapeutics (VKTX) reported a narrower-than-expected Q2 2026 loss of $1.10 per share, surpassing the Zacks Consensus Estimate of a $1.21 loss, despite a significant 92.4% surge in R&D expenses due to pipeline development, primarily for its lead obesity candidate VK2735. The company is …
Viking Therapeutics is moving its oral tablet formulation of VK2735 into Phase 3 trials in Q4 2026, building on its strong cash position of $502 million and two fully enrolled Phase 3 subcutaneous trials. The company aims for VK2735 to be the first oral …
Viking Therapeutics reported a significant net loss increase in Q2 2026 due to higher R&D expenses, yet remains optimistic about its obesity pipeline. The company highlighted progress in its VK2735 Phase III program, with upcoming oral trials, and the entry of VK3019 into Phase …
Viking Therapeutics (VKTX) stock has underperformed its GLP-1 peers in July, but CEO Brian Lian believes its obesity drug VK2735 could offer a competitive edge through multiple treatment options, including weekly injection, daily pill, and potentially less-frequent dosing for maintenance. The company's lead drug …
Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous VK2735 in Obesity Fully Enrolled and Advancing -- -- Oral Phase 3 VK2735 Trial Initiation Expected 4Q26 -- -- VK2735 Maintenance Dosing Data Expected 3Q26 -- …
Quick Read REGN sits 15% below its year-start price despite strong earnings, while MRNA has surged 177% into an August 5 FDA flu vaccine ruling. VKTX carries 175% analyst upside potential but remains pre-revenue, making its dual GLP-1/GIP Phase 3 obesity trials a binary …
Shares of Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech, have declined by 46% over the past two years. There are several reasons for this. First, longtime shareholders decided to pocket some profits after Viking Therapeutics reported excellent mid-stage results for its leading candidate, subcutaneous …
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Let's take a look at what these …
Insiders at Viking Therapeutics recently sold shares worth US$15 million, with the average selling price ranging from US$66.00 to US$89.00. This significant insider selling event could suggest that the stock might be overvalued, prompting investors to consider various valuation metrics. Despite the selling, the …
Viking Therapeutics (NASDAQ:VKTX) stock is under scrutiny for its cash burn ahead of its Q2 earnings report on July 29. Analysts expect increased losses due to surging research and operating expenses, prompting investor focus on cash levels, expenditure, and clinical trial timelines. The company …
This article provides financial information for Viking Therapeutics, Inc. (DUS:1VT) on the Düsseldorf Stock Exchange. It focuses on the company's revenue breakdown, including top segments and regional performance, sourced from FactSet and ICE Data Services.
Viking Therapeutics Inc (VKTX) is a clinical-stage biopharmaceutical company focused on treatments for metabolic and endocrine disorders, with lead programs including VK2735 and VK2809. The company's stock is currently trading at $34.77, down 1.75%, and analysts have a "Buy" rating with an average target …
Viking Therapeutics (VKTX) stock has seen significant returns over the past five years, but current valuations suggest it may be overvalued, particularly when considering its price-to-book (P/B) ratio. The high valuation is partly driven by excitement around new diabetes and metabolic therapies, though the …
Viking Therapeutics (VKTX.US) is scheduled to release its earnings report after the market closes on July 29. Investors will be observing this announcement for insights into the company's financial performance.
Search by ticker symbol or company name and select a result to open its chart.